Trials / Unknown
UnknownNCT01151358
Evaluation of Patient and Lesion Specific Prognostic Factors for Standard Radioimmunotherapy
Multicenter Prospective Evaluation of Patient- and Lesion Specific Prognostic Factors for Standard RadioImmunoTherapy With 90-Yttrium-labeled Anti-CD20 in Follicular Non-Hodgkin´s Lymphoma
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (estimated)
- Sponsor
- University Hospital, Saarland · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
MERIT-NHL as an addendum to the International Registry of Radioimmunotherapy (RIT registry) pooling clinical data of patients who suffered from a non-Hodgkin´s lymphoma also includes the documentation of the respective FDG-PET and CT-image files in an online archive. Based on these documented clinical and imaging data, the MERIT study group centrally performs an intra- as well as interindividual evaluation of follicular CD20+ lymphoma lesions before and after radioimmunotherapy. According to this, the aim of the MERIT-NHL study is to prospectively identify yet unknown patient- and lesion specific prognostic factors predicting patient´s outcome in line with the therapeutic modality radioimmunotherapy.
Conditions
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2011-12-01
- Completion
- 2011-12-01
- First posted
- 2010-06-28
- Last updated
- 2010-06-28
Locations
4 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01151358. Inclusion in this directory is not an endorsement.